Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585631 | 0.91 | JAK2 (0.64) | JAK2LMNAGAAMAPTHTR1B | |
| SCHEMBL5621969 | 0.82 | GAA (0.82) | JAK2LMNAGAAMAPTKDM4E | |
| SCHEMBL9045649 | 0.82 | GAA (0.82) | JAK2LMNAGAAMAPTKDM4E | |
| SCHEMBL24011910 | 0.80 | GAA (0.78) | JAK2LMNAGAAMAPT | |
| SCHEMBL9123832 | 0.80 | GAA (0.78) | JAK2LMNAGAAMAPT | |
| SCHEMBL15650290 | 0.80 | CYP1A2 (0.49) | LMNAGAAMAPTHTR1BHRH1 | |
| SCHEMBL2637278 | 0.80 | GAA (0.95) | JAK2LMNAGAAMAPTKDM4E | |
| SCHEMBL13948841 | 0.79 | HRH1 (0.63) | HTR1BHRH1HTR7LSS | |
| SCHEMBL30492994 | 0.79 | HTR7 (0.64) | LMNAHTR1BHRH1HTR7LSS | |
| SCHEMBL10989846 | 0.79 | HRH1 (0.62) | HTR1BHRH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| CN-1186318-C | Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them | SAVOIER LAB (FR) | 2005-01-26 | — | — | CN | disclosed |
| EP-1275641-B1 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-01-12 | — | — | EP | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6541471-B1 | Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist | LES LABORATOIRES SERVIER (FR) | 2003-04-01 | — | — | US | disclosed |
| CN-1397547-A | Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them | SAVOIER LAB (FR) | 2003-02-19 | — | — | CN | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1275641-A2 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | JAK2 1247/4885LMNA 187/4885GAA 907/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | JAK2 1384/4885LMNA 201/4885GAA 684/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | JAK2 1903/4885LMNA 1749/4885GAA 387/4885 |
| US-20060142266-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | JAK2 1384/4885LMNA 201/4885GAA 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.